Source: Arquivos de Neuro-Psiquiatria. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, TESTES NEUROPSICOLÓGICOS, DOENÇA DE ALZHEIMER
ABNT
NITRINI, Ricardo e STUDART NETO, Adalberto. Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease. Arquivos de Neuro-Psiquiatria, v. 83, n. 5, p. 4-5, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/87224. Acesso em: 22 abr. 2026.APA
Nitrini, R., & Studart Neto, A. (2025). Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease. Arquivos de Neuro-Psiquiatria, 83( 5), 4-5. doi:10.1055/s-0045-1808082NLM
Nitrini R, Studart Neto A. Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease [Internet]. Arquivos de Neuro-Psiquiatria. 2025 ; 83( 5): 4-5.[citado 2026 abr. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87224Vancouver
Nitrini R, Studart Neto A. Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease [Internet]. Arquivos de Neuro-Psiquiatria. 2025 ; 83( 5): 4-5.[citado 2026 abr. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87224
